Barclays PLC Increases Stock Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM)

Barclays PLC increased its holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) by 3,661,933.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 549,305 shares of the company’s stock after buying an additional 549,290 shares during the period. Barclays PLC’s holdings in Carisma Therapeutics were worth $539,000 as of its most recent SEC filing.

Separately, Point72 Asia Singapore Pte. Ltd. acquired a new position in Carisma Therapeutics during the second quarter worth about $40,000. 44.27% of the stock is owned by institutional investors.

Carisma Therapeutics Price Performance

Shares of NASDAQ:CARM opened at $0.44 on Friday. The company has a market cap of $18.37 million, a P/E ratio of -0.28 and a beta of 1.44. The business has a fifty day simple moving average of $0.75 and a 200-day simple moving average of $0.96. Carisma Therapeutics, Inc. has a 52 week low of $0.38 and a 52 week high of $2.94. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The company had revenue of $3.39 million during the quarter. Equities research analysts forecast that Carisma Therapeutics, Inc. will post -1.32 EPS for the current year.

Wall Street Analysts Forecast Growth

CARM has been the subject of a number of recent research reports. Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Evercore ISI reaffirmed an “in-line” rating and set a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. Finally, EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.94.

Carisma Therapeutics Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.